Clinical Research Directory
Browse clinical research sites, groups, and studies.
Magnesium Supplementation for the Prevention of Cisplatin-Induced Nephrotoxicity
Sponsor: Grigore T. Popa University of Medicine and Pharmacy
Summary
This prospective, randomized, open-label study evaluated whether intravenous magnesium sulphate added to standard hydration could reduce cisplatin-associated renal toxicity in adult patients with solid tumors receiving weekly cisplatin-based chemoradiotherapy. Participants were assigned to standard hydration with intravenous saline and furosemide or to the same hydration protocol supplemented with 1 g of intravenous magnesium sulphate before cisplatin administration. The primary outcome was early renal toxicity assessed 48 hours after cisplatin administration. Secondary outcomes included renal dysfunction at one year, changes in urinary kidney injury biomarkers (KIM-1, NGAL, and suPAR), hematological toxicity, and treatment response
Official title: Prevention of Cisplatin Nephrotoxicity in Cancer Patients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
43
Start Date
2021-03-01
Completion Date
2024-12-31
Last Updated
2026-10-14
Healthy Volunteers
No
Conditions
Interventions
Magnesium sulphate
1 g intravenously before cisplatin administration, administered with the pre-hydration regimen.
Furosemide
20 mg intravenously before cisplatin administration as part of the hydration protocol.
Saline (0.9% NaCl)
1 L of 0.9% sodium chloride before cisplatin and 1 L after cisplatin.
Locations (1)
Grigore T Popa University of Medicine and Pharmacy Iasi
Iași, Romania